Abstract
Caffeine is the oldest consumed psychoactive drug, present in coffee, cocoa, tea, among other products. Several conventional methods are used to analyze caffeine, for example, chromatography and spectrometry, but these methods are expensive when compared to electroanalytical methods. The objective of this study is to study the feasible applicability of electrochemical techniques for quantification of caffeine in medications. Cyclic voltammetry was performed on the platinum electrode in 0.5 M H2SO4 and after that differential pulse voltammetry was performed to obtain the linear relation between caffeine concentration and current. A linear response in the electroanalytical approach exists from 38.05±3.02 to 192.39±1.04 ppm with a limit of detection of about 9.09±0.72 ppm. This sensor may represent a new analytical tool for caffeine analysis, based on existing literature.
Keywords: Caffeine, platinum sensor, cyclic voltammetry, drugs.
Current Pharmaceutical Analysis
Title:Platinum Sensor for Quantifying Caffeine in Drug Formulations
Volume: 10 Issue: 4
Author(s): Danyelle Medeiros de Araujo, Chrystiane do Nascimento Brito, Severina Denise Sales de Oliveira, Djalma Ribeiro da Silva, Carlos A. Martinez-Huitle and Cícero Flavio Soares Aragao
Affiliation:
Keywords: Caffeine, platinum sensor, cyclic voltammetry, drugs.
Abstract: Caffeine is the oldest consumed psychoactive drug, present in coffee, cocoa, tea, among other products. Several conventional methods are used to analyze caffeine, for example, chromatography and spectrometry, but these methods are expensive when compared to electroanalytical methods. The objective of this study is to study the feasible applicability of electrochemical techniques for quantification of caffeine in medications. Cyclic voltammetry was performed on the platinum electrode in 0.5 M H2SO4 and after that differential pulse voltammetry was performed to obtain the linear relation between caffeine concentration and current. A linear response in the electroanalytical approach exists from 38.05±3.02 to 192.39±1.04 ppm with a limit of detection of about 9.09±0.72 ppm. This sensor may represent a new analytical tool for caffeine analysis, based on existing literature.
Export Options
About this article
Cite this article as:
Araujo Medeiros de Danyelle, Brito do Nascimento Chrystiane, de Oliveira Sales Severina Denise, Silva Ribeiro da Djalma, Martinez-Huitle A. Carlos and Aragao Flavio Soares Cícero, Platinum Sensor for Quantifying Caffeine in Drug Formulations, Current Pharmaceutical Analysis 2014; 10 (4) . https://dx.doi.org/10.2174/1573412910666140630191329
DOI https://dx.doi.org/10.2174/1573412910666140630191329 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Genetics of Polygenic Hypertension from Animal Models to Humans
Current Hypertension Reviews The Clinical Pharmacology of Short Acting Analgo-Sedatives in Neonates
Current Clinical Pharmacology Role of Endothelial Nitric Oxide in Cerebrovascular Regulation
Current Pharmaceutical Biotechnology Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery A Review of Voltammetric Methods for Determination of Dopamine Agonists
Current Analytical Chemistry Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Nitric Oxide-NASIDS Donor Prodrugs as Hybrid Safe Anti-inflammatory Agents
Current Topics in Medicinal Chemistry Corticosteroids in Sepsis: Pathophysiological Rationale and the Selection of Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Development and Validation of a Simple LC-UV Method to Assay Doxazosin in Polymeric Nanocapsules and Tablets
Current Pharmaceutical Analysis Ezogabine: Development and Role in the Management of Epileptic Seizures
Mini-Reviews in Medicinal Chemistry Snake Venom Prothrombin Activators Similar to Blood Coagulation Factor Xa
Current Drug Targets - Cardiovascular & Hematological Disorders Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits
Current Pharmaceutical Biotechnology Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Overexpression of a Modified Amaranth Protein in Escherichia coli with Minimal Media and Lactose as Inducer
Recent Patents on Biotechnology